<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO>WSJ911119-0012</DOCNO><DOCID>911119-0012.</DOCID><HL>   Technology Brief -- Stryker Corp.:   Human Testing Approved   For Bone Growth Device</HL><DATE>11/19/91</DATE><SO>WALL STREET JOURNAL (J), NO PAGE CITATION</SO><CO>   STRY</CO><MS>TECHNOLOGY (TEC)</MS><IN>MEDICAL andamp; BIOTECHNOLOGY, GENETIC RESEARCH, PROSTHETICS (MTC)</IN><NS>NEW PRODUCTS andamp; SERVICES (PDT)SCIENCE andamp; TECHNOLOGY (SCN)</NS><GV>FOOD AND DRUG ADMINISTRATION (FDA)</GV><RE>MASSACHUSETTS (MA)MICHIGAN (MI)NORTH AMERICA (NME)UNITED STATES (US)</RE><LP>   Stryker Corp. and Creative BioMolecules Inc. said the Foodand Drug Administration has approved human clinical studiesfor Stryker's bone growth device.   In preclinical studies, the Osteogenic Protein Device hashelped to provide a scaffold for bone growth when implantedinto bone defect sites. The first human implants are expectedin January, the companies said.</LP><TEXT>   Creative BioMolecules, a Hopkinton, Mass.,biopharmaceutical concern, developed the protein known asOP-1 through a research and development program funded byStryker, a Kalamazoo, Mich., manufacturer of surgical andmedical products.</TEXT></DOC>